Treatment Strategies of Acute Myeloid Leukemia Relapses after Allogeneic Stem Cell Transplantation: Evidence from the GITMO Nationwide Italian Registry
Observational analysis highlights the impact of disease burden on survival in AML patients after relapse post-transplant, suggesting early treatment enhances outcomes.
Key Points
Relapse mortality significantly decreases in AML patients receiving early treatment with immunotherapy, especially DLI.
Overall survival was 55% at one year for AML patients post-transplant, while relapse mortality was notably high at 39%.
Cox regression analysis revealed that low disease burden at relapse is independently associated with improved overall survival.
The use of hypomethylating agents showed a promising safety profile with no significant effect on treatment-related mortality regardless of disease burden.